Physician profile
David W Seitsinger
NPI 1568492577
$8,393.83
in general payments reported to CMS, 2019-2025
44 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $1,185 · 2021: $550 · 2022: $908 · 2023: $1,433 · 2024: $1,412 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,373.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,398.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $935.84 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $797.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $563.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $478.65 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $470.05 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $465.91 | 2020-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.61 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $286.89 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $274.98 | 2019-2025 | Evenity, Prolia, Prolia |
| Merck Sharp & Dohme LLC | $259.51 | 2019-2023 | Belsomra |
| Exact Sciences Corporation | $194.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $161.41 | 2021 | |
| Abbott Laboratories | $123.31 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $119.20 | 2023-2025 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seitsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.